Filing Details
- Accession Number:
- 0001062993-22-001041
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-01-13 19:54:53
- Reporting Period:
- 2022-01-11
- Accepted Time:
- 2022-01-13 19:54:53
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1177648 | Enanta Pharmaceuticals Inc | ENTA | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1646976 | Nathalie Adda | C/O Enanta Pharmaceuticals, Inc. 500 Arsenal Street Watertown MA 02472 | Sr. Vp & Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-01-11 | 9,200 | $43.46 | 42,102 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2022-01-11 | 3,336 | $30.00 | 45,438 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-01-11 | 12,536 | $70.13 | 32,902 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2022-01-11 | 9,200 | $0.00 | 9,200 | $43.46 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2022-01-11 | 3,336 | $0.00 | 3,336 | $30.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 36,820 | 2025-06-29 | No | 4 | M | Direct | |
| 31,664 | 2026-11-18 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021.
- The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.90, inclusive.
- 100% of the shares subject to the option are fully vested and exercisable.
Billionaire Hedge Funds
